IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

被引：0
|
作者：
Eraslan, Lale Erdem [1 ]
van den Bent, Martin [1 ]
Kros, Johan [1 ]
Oosterkamp, Hendrika [2 ]
Walenkamp, Annemiek [3 ]
Beerepoot, Laurens [4 ]
Hanse, Monique [5 ]
Buter, J. [6 ]
Honkoop, Aafke [7 ]
van der Holt, Bronno [1 ]
Vernhout, R. M. [1 ]
Smitt, Peter Sillevis [1 ]
Taal, Walter [1 ]
French, Pim [1 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
[2] MC Haaglanden, The Hague, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Elisabeth Hosp, Tilburg, Netherlands
[5] Catharina Hosp, Eindhoven, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[7] Isala Klin, Zwolle, Netherlands
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou256.10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GE-10
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Baseline FET-PET kinetic pattern predicts outcome in recurrent GBM patients prior to bevacizumab therapy
    Horky, Laura
    Reardon, David
    Huang, Raymond
    Kijewski, Marie
    Wen, Patrick
    Gerbaudo, Victor
    Semer, James
    Sticka, William
    Strader, Christopher
    Park, Mi-Ae
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [32] Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data
    Cloughesy, Timothy Francis
    Finocchiaro, Gaetano
    Belda, Cristobal
    Recht, Lawrence
    Brandes, Alba Ariela
    Pineda, Estela
    Mikkelsen, Tom
    Chinot, Olivier L.
    Balana, Carmen
    Macdonald, David R.
    Westphal, Manfred
    Hopkins, Kirsten
    Weller, Michael
    Liu, Bo
    Bruey, Jean-Marie
    Verret, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Pressure to respond: Hypertension predicts clinical benefit from bevacizumab in recurrent ovarian cancer
    Nick, A.
    Stone, R.
    Soliman, P.
    Sood, A.
    Gershenson, D.
    Coleman, R.
    Ramirez, P.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S37 - S37
  • [34] EFFICACY AND SAFETY OF BEVACIZUMAB (BV) AND IRINOTECAN (I) IN ELDERLY PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORM (GBM): A MONOCENTRIC RETROSPECTIVE STUDY
    Robert, M.
    Leux, C.
    Gourmelon, C.
    Campone, M.
    Frenel, J.
    ANNALS OF ONCOLOGY, 2014, 25
  • [35] ARE WE USING TOO MUCH BEVACIZUMAB IN OUR GBM PATIENTS?
    Ajlan, Abdulrazag
    Thomas, Piia
    Thomas, Reena
    Nagpal, Seema
    Recht, Lawrence
    NEURO-ONCOLOGY, 2014, 16
  • [36] Bevacizumab (BEV)-based therapy in the treatment of recurrent glioblastoma (GBM) in patients (PTS) treated at a Brazilian cancer center.
    Munhoz, Rodrigo Ramella
    Freitas Melro Braghiroli, Maria Ignez
    De Mendonga Rego, Juliana Florinda
    Hoff, Paulo Marcelo
    Feher, Olavo
    Katz, Artur
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] PHASE 1 TRIAL OF BEVACIZUMAB PLUS TPI 287 IN ADULTS WITH RECURRENT GLIOBLASTOMA (GBM)
    Conrad, Charles
    Yung, W. K. Alfred
    deGroot, John
    Gilbert, Mark
    Loghin, Monica
    Penas-Prado, Marta
    Tremont, Ivo
    Silberman, Sandra
    Picker, Donald
    NEURO-ONCOLOGY, 2013, 15 : 106 - 106
  • [38] Phase II trial of enzastaurin (Enz) with bevacizumab (BV) in adults with recurrent glioblstoma (GBM).
    Moustakas, A.
    Iwamoto, F. M.
    Kreisl, T. N.
    Sul, J.
    Kim, L. J.
    Butman, J. A.
    Albert, P. S.
    Fine, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] What Is the Benefit of Bevacizumab Combined with Chemotherapy in Patients with Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Malignancies?
    Cheng, X.
    Moroney, J. W.
    Levenback, C. F.
    Fu, S.
    Jaishuen, A.
    Kavanagh, J. J.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 566 - 572
  • [40] Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
    Burger, Michael C.
    Breuer, Stella
    Cieplik, Hans C.
    Harter, Patrick N.
    Franz, Kea
    Baehr, Oliver
    Steinbach, Joachim P.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11):
12345